MVZ CCB Frankfurt Und Main-Taunus GbR
- Address
- lock Available on a paid plan
MVZ CCB Frankfurt Und Main-Taunus GbR - Multispecialty Clinical Research Center
MVZ CCB Frankfurt Und Main-Taunus GbR is a comprehensive medical research center engaged in diverse clinical trials across multiple therapeutic areas. The center demonstrates expertise in investigating novel treatment approaches for complex diseases, with particular emphasis on optimizing therapeutic outcomes through innovative combination therapies and advanced diagnostic techniques.
- Hematologic malignancies research, focusing on multiple myeloma treatment optimization with immunotherapy combinations and minimal residual disease assessment
- Cardiovascular interventional studies evaluating contrast medium-sparing strategies and prevention of kidney complications in peripheral arterial disease
- Lipid metabolism disorders and atherosclerotic cardiovascular disease management through novel cholesterol-lowering agents
The research portfolio spans from oncology and hematology to cardiovascular medicine, demonstrating the center's capability in managing complex Phase III randomized controlled trials. Particular research strengths include advanced peripheral vascular interventions, investigation of hypercholesterolemia therapies, and assessment of minimal residual disease in cancer patients. The center actively participates in multicenter international studies evaluating both drug therapies and procedural innovations aimed at improving patient outcomes while minimizing treatment-related complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novo Nordisk A/S1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S6trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ CCB Frankfurt Und Main-Taunus GbR
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ziltivekimab | 4 | Unknown | 2021-09-24 | 2024-08-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.